BioStable Science & Engineering, Inc.

BioStable Science & Engineering, Inc. develops innovative aortic valve repair technologies, focusing on advanced annuloplasty devices aimed at enhancing cardiac surgery outcomes and improving patient care. Founded in 2008, BioStable Science & Engineering, Inc. is based in Austin, US, and specializes in developing aortic valve repair technology.

The company has successfully raised funding, including a Series B round of USD 4. 8 mn led by Sante Ventures. Since its inception, the firm has completed a total of 4 deals, with the most recent occurring on February 25, 2020. The CEO, John Wheeler, has a background in medical technology and innovation.

BioStable Science & Engineering specializes in advanced aortic valve repair technologies, focusing on the HAART 300™ and HAART 200™ aortic annuloplasty devices. These products are designed to resize and reshape the aortic valve annulus, aiming to reduce dilatation and stabilize the valve, thereby decreasing the risk of recurrent annular dilatation. The HAART 300™ targets trileaflet aortic valves, while the HAART 200™ is specifically engineered for bicuspid aortic valve restoration. These devices are utilized in various clinical settings, addressing conditions such as isolated aortic insufficiency, aortic aneurysms with aortic insufficiency, dissections with aortic insufficiency, and other related applications.

The company primarily serves cardiothoracic surgeons and medical institutions involved in cardiac care across North America and Europe, where the demand for innovative valve repair solutions continues to rise. The revenue model of BioStable Science & Engineering is primarily based on the direct sale of its flagship products, the HAART 300™ and HAART 200™ aortic annuloplasty devices, to hospitals and surgical centers that perform valve repair procedures. Transactions typically occur through a B2B structure, where the company establishes partnerships with medical institutions and surgical teams, facilitating training and support alongside device sales. Pricing structures are determined based on the specific needs of the healthcare facilities, which may include bulk purchasing agreements or individual device sales.

Additionally, the company invests in training programs and educational resources to ensure effective use of its technologies, thereby enhancing customer satisfaction and fostering long-term client relationships in the cardiothoracic surgical community. BioStable Science & Engineering is focused on launching new products aimed at enhancing its aortic valve repair solutions, with plans for specific product releases in the near future. The company is targeting expansion into additional European and North American markets by 2023, aiming to establish new partnerships with medical institutions to broaden its reach. The recent funding of USD 4.

8 mn from the Series B round will be utilized to support these initiatives and enhance product development efforts, ensuring the company remains competitive in the evolving healthcare landscape.